Published in Hepatitis Weekly, November 20th, 2000
"The majority of persons infected with HIV from intravenous drug use are co-infected with HCV and are at higher risk of progression to advanced liver disease and hepatocellular carcinoma than their HIV negative counterparts," stated F.C. Baldamus and colleagues from Harvard School of Medicine, Massachusetts. "Combination therapy with interferon-alpha2b and ribavirin is expensive, but has been shown to be cost-effective in HIV negative persons. Our objective was to assess the cost-effectiveness of combination therapy for HCV in HIV...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.